Omar Kaseb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A new drug application has been submitted to the FDA for the combination of rivoceranib and camrelizumab as a first-line treatment option for patients with unresectable hepatocellular carcinoma.

United statesAhmed omar kasebSaeho chongDivision of cancer medicineDepartment of gastrointestinal medical oncologyUniversity of texas md anderson cancer centerOmar kasebGastrointestinal medical oncologyCancer medicineCancer centerNational medical products administration